Invitation to investors and media meeting on January 9, 2015 at 10:00 am (CET)

Solna (Sweden) – December 19, 2014 – The Management of Aerocrine AB hereby invites investors, analysts and the media to a meeting at Summit, Grev Turegatan 30 in Stockholm, on this day, Friday January 9, 2015 at 10:00 am (CET). The CEO Scott Myers will hold a presentation about the Company, its planned rights issue and future plans.

Scott Myers and Mats Carlson, VP Global Business Operations, will be available for questions after the presentation.

The presentation will be available on demand on the Aerocrine AB website in the afternoon the same day.

For participation please e-mail: hearings@financialhearings.com or sign up for the meeting on www.financialhearings.com.

A warm welcome!

For more information, please contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368 0336

About Aerocrine

Aerocrine AB is a medical product company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. For more information, please visit www.aerocrine.com and www.niox.com.